Dr Lal PathLabs : Record Date

July 28, 2022
National Stock Exchange of India Limited	BSE Limited
Exchange Plaza,	15th Floor, Phiroze Jeejeeboy Towers
Bandra Kurla Complex, Bandra (E),	Dalal Street,
Mumbai - 400051	Mumbai - 400001

Subject: Outcome of Board Meeting held on July 28, 2022

Ref: Compliances under SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 ("Listing Regulations")

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. July 28, 2022 approved Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended June 30, 2022.

A copy of the Results along with Limited Review Report issued by the Statutory Auditors M/s Deloitte Haskins & Sells, LLP on such financials for the first quarter ended June 30, 2022 is attached herewith.

At the said Meeting, the Board of Directors have also declared an interim dividend of Rs. 6/-per equity share (i.e. 60% on a face value of Rs. 10/- per share) for the FY 2022- 23.

Pursuant to Regulation 42 of Listing Regulations, the Board has fixed Record Date for the purpose of payment of interim dividend for FY 2022-23 as detailed below:

Symbol	Type of	Book	Record Date	Purpose
	security	Closure
		both days
		inclusive
NSE:	Equity	Not	Tuesday,	Payment	of	interim
LALPATHLAB		Applicable	August 9, 2022	dividend for FY 2022-23
BSE: 539524

The interim dividend will be paid by the Company on or before August 26, 2022.

Classification: Internal

The Board Meeting commenced at 11.00 A.M. and the item related to the Financial Results for the first quarter ended June 30, 2022 was approved by the Board at 1:00 P.M. The Board Meeting is still continuing for discussing other Agenda Item(s).

We request you to please take the same on record.

Thanking You,

Encl: As above

Classification: Internal

Deloitte

Haskins & Sells LLP

Chartered Accountants

7th Floor Building 10 Tower B

DLF Cyber City Complex DLF City Phase 11 Gurugram-122 002 Haryana, India

Tel: [phone]

Fax: [phone]

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

To The Board of Directors of

Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Dr. Lal PathLabs Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30 June, 2022 ("the Statement") being submitted by the Parent pursuant to the requirement of - Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a c_oriclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (!CAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities listed in Annexure A.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Regd. Oif,ce: One lnlternat;or,al Centtcr, Towe:r 3, 32nd Fioor, Sen..pati Bapat Marg, Elphinst,;,ne Ro;id (West), Mumbai-400 013, MahaI ashtra, India. (LLP ldentif.cation No. MB 8737)

Deloitte	& Sells LLP
Haskins

6. The consolidated unaudited financial results includes the interim financial information/ financial results of four subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total revenue of Rs. 46.16 million for the quarter ended 30 June, 2022, total loss after tax of Rs. 2.03 million for the quarter ended 30 June, 2022 and total comprehensive loss of Rs. 2.95 million for the quarter ended 30 June, 2022, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information/ financial results certified by the Management.

For Deloitte Haskins & Sells LLP

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)

�frr7'��-
	Ji	�	ndra Ag·arwal
		Partner
	(Membership No. 87104)
(UDIN:	2-2o'b7 104 AN,� PC. 1- ;:,o9 )

Place: Gurugram

Date: 28 July, 2022

Deloitte

Haskins & SellsLLP

Annexure A

List of entities consolidated

1. Parent Company: Dr. Lal PathLabs Limited
2. Subsidiaries held directly

S. No. Name of the Entity

• Paliwal Diagnostics Private Limited
  2 Paliwal Medicare Private Limited
  3 APL Institute of Clinical Laboratory & Research Private Limited
  4 Dr. Lal PathLabs Nepal Private Limited
  5 Dr. Lal PathLabs Banqladesh Pvt. Ltd.
  6 Dr. Lal Ventures Private Limited
  7 PathLabs Unifiers Private Limited

8

Dr. Lal PathLabs Kenva Private Limited

.

1. • Suburban Diagnostics (India) Private Limited (w.e.f 12 November, 2021)
2. Subsidiaries held indirectly

S. No.

1

2

3

Name of the Entity

Centrapath Labs Private Limited

APRL PathLabs Private Limited

Chanre Laboratory Private Limited